BioMatrix Specialty Pharmacy (BioMatrix) strengthened its relationship with AscellaHealth with the recent announcement that it was awarded preferred network status with AscellaHealth for both intravenous and subcutaneous immunoglobulin (IG) therapy treating patients in the neurology, immunology, transplant, and rare disease space.
AscellaHealth is a national Specialty PBM serving commercial, Medicare, and Medicaid health plans. The organization includes over 1 million covered lives and works to provide high quality care for patients and substantial cost savings for plan sponsors.
BioMatrix offers comprehensive, nationwide specialty pharmacy services and digital health technology solutions for patients with chronic, difficult to treat conditions. The specialty pharmacy offers a tailored approach for a wide range of therapeutic categories, improving health and empowering patients to experience a higher quality of life.
The decision to include BioMatrix in the PBM’s national network was based on overall clinical expertise, extensive IG experience across a broad range of therapeutic categories, operational efficiencies, data reporting capabilities, and competitive pricing model. Effective October 6, 2020, BioMatrix is one of the specialty pharmacies selected by the PBM to hold preferred provider status.
Earlier this year, BioMatrix was awarded preferred network status for AscellaHealth’s bleeding disorder patient population. At the time, BioMatrix became one of just four specialty pharmacies selected by the PBM to hold preferred provider status.
Our partnership creates value by uniting providers and other healthcare stakeholders to simplify the patient journey, improve patient health, and appropriately controlling specialty drug spend for plan sponsors of AscellaHealth.”
Takeaway: The companies offer a patient-centric approach to simplify the patient journey and control specialty drug spend for plan sponsors